Fig. 8: EMRMs have a greater glycolytic capacity than BMRMs.

a, b Real-time changes and quantifications of the ECAR (a) and OCR (b) in EMRMs and BMRMs at baseline or stressed with oligomycin/FCCP. Data are representative of three independent experiments (n = 3 per group). c Real-time changes and quantification of the ECAR in EMRMs and BMRMs sorted from Immune complex (IC)-treated mice at baseline or stressed with oligomycin/FCCP. Data are pooled from two independent experiments. (n = 5 for IC-EMRMs; n = 6 for IC-BMRMs). d Ex vivo glucose uptake in EMRMs and BMRMs sorted from PBS (Vehicle) or IC-treated mice. RMs were sorted and treated with 2-DG for 30 min, followed by measuring the level of its product 2DG6P by luminescence reader. Data are pooled from two independent experiments. (Vehicle: n = 7 for EMRMs and BMRMs; IC: n = 6 for EMRMs and n = 8 for BMRMs). e TNF production in LPS-stimulated EMRMs and BMRMs as in Fig. 7f together with or without glucose analog 2-DG. Data are pooled from two independent experiments and each dot represents cells obtained from individual sorting. (2-DG - group: n = 4 for EMRMs and n = 6 for BMRMs; 2-DG-1:1 group: n = 6 for EMRMs and n = 4 for BMRMs; 2-DG-2:1 group: n = 2 for EMRMs and BMRMs). All data are presented as mean ± s.e.m. p-values by two-way ANOVA analysis are indicated in the left panel of a–c and by two-tailed unpaired t-test in the right panel of a–c and d, e. Source data are provided as a Source Data file.